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N-acetylprocainamide (NAPA) is said to have class III
antiarrhythmic drug properties. The effects of NAPA
(25 mg/kg intravenously) on sustained, stable, reentrant
atrial flutter induced in 12 conscious dogs using a sterile
pericarditis model were studied and compared with the
effects of quinidine (5 mg/kg intravenously) given on a
different day in 10 of the same 12 dogs. The effects of
these drugs on atrial excitability, the atrial effective reo
fractory period and intraatrial conduction time mea-
sured during rapid atrial pacing performed during sinus
rhythm were also compared. The mean NAPAand quin-
idine serum levelswere 17.7 and 7.1 JLg/ml, respectively.
Both NAPAand quinidine immediately prolonged the
atrial flutter cycle length in all dogs, from 118 ± 15 to
141 ± 18 ms and from 119 ± 17 to 153 ± 21 ms,
respectively (both p < 0.001), and then terminated atrial
flutter in II of the 12 NAPA studies and in 6 of the 10
quinidine studies. Neither drug affected atrial excita-
bility. Both NAPA and quinidine increased the atrial
N-acetylprocainamide (NAPA) , a major metabolite of pro-
cainamide in humans (1,2) , is known to have antiarrhythmic
properties (3- 7). It prolongs the effective refractory period
of most cardiac tissue by increasing the action potent ial
duration , but has little effect on conduction (class III anti-
arrhythmic properties). The long-term effects of NAPA on
cardiac arrhythmias in humans, especially on ventricular
arrhythmias, have been studied previously (8-10). How-
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effective refractory period significantly, from 138 ± 17
to 168 ± 20 ms (p < 0.001) and from 136 ± 14 to 148
± 16 ms (p < 0.01), respectively. NAPA did not change
intraatrial conduction time measured during atrial pac-
ing at 150 beats/min, but during atrial pacing at 300
beats/min, it prolonged it from 51 ± 9 to 54 ± 10 ms
(p < 0.05), and at 400 beats/min, from 52 ± 10 to 64
± 13 ms (p < 0.001). Quinidine prolonged intraatrial
conduction time during atrial pacing at all three rates,
from 45 ± 8 to 49 ± 8 ms, 47 ± 7 to 52 ± 8 ms and
50 ± 8 to 56 ± 8 ms (all p values < 0.001), respectively.
It is concluded that I ) N-acetylprocainamide (NAPA)
has class III antiarrhythmic properties; 2) at rapid rates,
NAPA's effects are indistinguishable from those of quin-
idine because NAPA not only increases the atrial effec-
tive refractory period , but also prolongs intraatrial con-
duction time; and 3) NAPA effectively interrupts atrial
flutter in this experimental animal model.
(1 Am CoIl Cardiol1987;9:1332-8)
ever, little is known of its short-term effects when it is
admini stered during sustained , reentrant tachyarrhythmias.
Recently, we developed a reliable canine model of sus-
tained , stable atrial flutter created simply by inducing sterile
pericarditis (I I) . In this model , atrial flutter can be repeat-
ed y induced in both the conscious and open chest states .
Our previous studies (12) have shown that atrial flutter in
this model is due to circus movement (that is, reentry) in
the right atrium, which does not necessarily require an an-
atomic obstacle in the circuit. In an effort to characterize
further the nature of the atrial flutter in this model, which
has a clinical counterpart (l 1-13) , we thought it would be
useful to administer a class III antiarrhythmic agent , that
is, an agent that only prolongs refractorine ss, and compare
it with a class IA antiarrhythmic agent, that is, an agent
that not only prolongs refractor iness but also slows con-
duct ion. In the present study, we administered NAPA (a
class III antiarrhythmic agent) dur ing sustained atrial flutter
induced in this animal model in the conscious state and
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noted its short-term effects on atrial flutter. Its effects on
several atrial electrophysiologic properties also were deter-
mined and were correlated with the effects on atrial flutter.
Furthermore, the effects of quinidine (a class IA antiar-
rhythmic agent) on this same model of atrial flutter were
comparatively studied,
Methods
Preparation of materials. Studies were performed in
12 adult mongrel dogs weighing 15 to 26 kg in which sterile
pericarditis had been created, and subsequently, sustained,
stable atrial flutter could be repeatedly induced in the con-
scious, nonsedated state.
Creation of sterile pericarditis (ll). Dogs were anes-
thetized with sodium thiopental (15 mg/kg body weight)
administered intravenously, and mechanical ventilation was
maintained using a Harvard respirator. Using sterile tech-
nique, a right thoracotomy was performed at the fourth
intercostal space, The heart was exposed and suspended in
a pericardial cradle, Three pairs of stainless steel wire elec-
trodes coated with FEP polymer except at the tip (0 Flexon,
Davis and Geck) were sutured On the following three atrial
sites: sulcus terminalis of the right atrium, Bachmann's bun-
dle region and posteroinferior left atrium close to the coro-
nary sinus. The interelectrode distance of each pair was
about 5 mm. The other ends of these wire electrodes were
then brought out through the chest wall and exteriorized in
the posterior neck close to the posterior midline, The atrial
surface was generously dusted with sterile talcum powder
and a single layer of gauze was put on the right and left
atrial free walls. The pericardium was closed and then the
chest was closed. The dogs were given antibiotics and an-
algesics and allowed to recover.
Electrophysiologic study in the conscious, nonsedated
state. On successive postoperative days, electrophysiologic
study, including induction of atrial flutter and observation
of each drug's effects, was performed in the conscious,
nonsedated state. Three surface electrocardiograms (ECGs)
(leads I, II and III) and three bipolar electrograms obtained
from the sulcus terminalis, Bachmann's bundle region and
posterorinferior left atrium (filtered between a bandpass of
12 to 500 Hz) were monitored on an oscilloscope and re-
corded simultaneously on photographic paper using an Elec-
tronics for Medicine DR-12 switched-beam oscilloscopic
recorder. The data were also recorded simultaneously on a
Honeywell 5600C FM tape recorder for subsequent play-
back and analysis. All measurements were made from data
recorded at a paper speed of 100 mm/s. A modified Med-
tronic 5325 programmable, battery-powered stimulator with
a pulse width of 1.8 ms was used for atrial pacing.
Measurements of atrial electrophysiologic properties.
The threshold of excitability was determined at three atrial
sites (sulcus terminalis, Bachmann's bundle region and pos-
teroinferior left atrium) during atrial pacing at a rate of 150
beats/min and the mean value of three measured thresholds
was determined (mean threshold of excitability). Using a
twice threshold pacing stimulus at each atrial site, the ef-
fective refractory period was then determined at each of the
three atrial sites: after an eight beat train of atrial paced
beats at 150 beats/min, a single premature atrial beat was
introduced to scan diastole at 5 ms decrements. The mean
value of the effective refractory periods at the three atrial
sites was then mathematically calculated (mean effective
refractory period). In five dogs, the effective refractory pe-
riod was also determined during rapid atrial pacing at a rate
of 300 beats/min.
Rapid atrial pacing at rates of 150, 300 and 400 beats/min
was performed from the sulcus terminalis using an output
of 20 rnA (the maximal output of the stimulator used in this
study), and time intervals between the stimulus artifact and
the electrogram recorded at the posteroinferior left atrium
(ST-PLA interval) and between the electrograms recorded
at the Bachmann's bundle region and the posteroinferior left
atrium (BB-PLA interval) were measured at each pacing
rate. These time intervals were used as markers of intraatrial
conduction time during rapid rates. A suprathreshold stim-
ulus of 20 rnA was used to assure constant 1:1 atrial capture
at the very rapid pacing rates studied. This also permitted
comparison of conduction times at each of the pacing rates
(14).
Induction of atrial flutter. In this study, stable atrial
flutter was defined as a tachycardia with an atrial rate 240
beats/min, showing a constant atrial cycle length and a con-
stant atrial electrogram morphology characteristic of atrial
flutter (13), and continuing for at least 15 minutes after
initiation. The induction of atrial flutter was made by either
introduction of premature atrial beats or by rapid atrial pac-
ing at rates of 400 to 650 beats/min from the sulcus ter-
minalis or Bachmann's bundle region or posteroinferior left
atrium (\ I).
Study protocol. After recording the baseline ECG and
three atrial electrograms, the atrial electrophysiologic prop-
erties described were first determined (first determination).
Then the induction of atrial flutter was attempted. When
stable atrial flutter was induced, the atrial flutter cycle length
and the ventricular rate were observed for any changes over
a time course of at least 15 minutes to confirm the stability
of induced atrial flutter. Atrial flutter was then terminated
by rapid atrial pacing at rates higher than the flutter rate
(control atrial flutter episode).
After a control atrial flutter episode was converted to
sinus rhythm. the atrial electrophysiologic properties were
again determined (second determination) and compared with
previous values to see if the induction of atrial flutter had
any influence on them. Then a second episode of atrial flutter
was induced in the same way as in the control episode.
Consequently, the same atrial flutter as that of the control
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Atrial Flutter
Table 1. Characteristics of Control Atrial Flutter Before
N-acetylprocainamide and Quinidine Studies
Results
Characteristics of atrial flutter induced in the present
canine model. In all dogs, stable atrial flutter that was
sustained for at least IS minutes was repeatedly induced in
the conscious, nonsedated state on at least 2 different days
after creation of pericarditis. Figure I shows a representative
example of atrial flutter induced, in this instance, before N-
acetylprocainamide (NAPA) administration (that is, it was
the control atrial flutter before NAPA administration). Note
that both the morphology of all atrial electro grams and their
relative activation sequence are constant over the 15 minute
period. Furthermore, the atrial flutter cycle length and ven-
tricular rate also are remarkably constant over this period
(I1,I3).
The characteristics of all control atrial flutter episodes
induced before drug studies are shown in Table 1. The
coefficients of variation of the atrial flutter cycle length and
the ventricular rate were determined for a period from 5 to
IS minutes after initiation of atrial flutter. Because these
values were negligible, atrial flutter induced in this study
episode (atrial flutter with the same atrial flutter cycle length,
the same morphology of atrial electrogram and the same
relative activation sequence of three atrial electrograms as
in the control episode) was induced in all 12 dogs. Five
minutes after the induction of the second episode of atrial
flutter, N-acetylprocainamide (NAPA) (25 mg/kg) or quin-
idine gluconate (5 mg/kg) was administered intravenously
over a 3 minute period and the drug's effects on the atrial
flutter cycle length and ventricular rate were noted. If atrial
flutter was still present 10 minutes after drug administration,
the atrial flutter was then terminated by rapid atrial pacing.
The same atrial electrophysiologic properties were again
measured (third determination) to establish the drug's ef-
fects. Finally, an attempt to reinduce atrial flutter was made,
using the pacing protocol previously used to determine whether
the flutter could be reinduced.
Blood was sampled 10 to 15 minutes after administration
of each drug to obtain the drug serum level. The measure-
ment was performed using fluorescent immunoassay for the
NAPA level and spectrofluorometry for the quinidine level.
In two dogs, only the effect of NAPA was studied. In
10 dogs, the effect of NAPA and of quinidine was studied
on different days. The order of testing in these 10 dogs
varied from dog to dog: in six dogs, the NAPA study pre-
ceded the quinidine study by a mean interval of 36 hours
(range 24 to 96); in the remaining four dogs, the latter
preceded the former by a mean interval of 48 hours (range
24 to 96). Consequently, the effects of NAPA were studied
in 12 dogs and those of quinidine in to dogs 3.3 ± 1.7
and 3.1 ± 1.7 (mean ± SD) days, respectively, after cre-
ation of sterile pericarditis.
Statistics. All results are shown as mean ± I SD and
statistical analysis was performed using a paired or unpaired
Student's t test.
Atrial Rutter cycle length (ms)
Coefficient of variation (%)
Ventricular rate (beats/min)
Coefficient of variation (%)
NAPA = N-acetylprocainamide.
Before
NAPA Study
(n = 12)
119 ± 14
0.7
188 ± 48
4.1
Before
Quinidine Study
(n = 10)
119 ± 12
0.7
201 ± 49
4.2
Figure I. Control episode of atrial flutter induced before admin-
istering N-acetylprocainamide. Electrocardiographic (ECG) leads
I, II and 1lI are recorded simultaneously with bipolar electrograms
at the sulcus terminalis site (ST), Bachmann's bundle site (BB)
and posteroinferior left atrium (PLA) at 2, 5, 10 and 15 minutes
after induction of atrial flutter. AFI-CL = atrial flutter cycle length;
V-rate = ventricular rate. See text for discussion.
Figure 2. Representative example of the effects of N-acetylpro-
cainamide (NAPA) on atrial flutter. This episode of atrial flutter
was reinduced after the control episode shown in Figure I. Re-
cordings are before (left panel) and 30 seconds after NAPA admin-
istration (right panel). NAPA increased the atrial flutter cycle
length (AFI-CL) and then interrupted the atrial flutter 35 seconds
after its administration. Abbreviations as in Figure I. See text for
discussion.
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Figure 3. The timecourseof change in the atrial flutter
cycle length (AFI-CL) and ventricular rate (V-Rate)
occurring during a control episode of atrial flutter and
duringan N-acetylprocainamide study (left panel), and
during a control episode of atrial flutter and during a
quinidine study (right panel) are shown. Each panel
corresponds to the recordings shown in Figures 2 and
4, respectively.
was considered to be stable enough to determine any short-
term effects of either NAPA or quinidine administration.
Effects of NAPA and quinidine on atrial flutter. The
mean serum level of NAPA was 17.7 ± 2.5 JLg/ml and
that of quinidine was 7.1 ± 1.4 JLg/ml. In all dogs, both
NAPA and quinidine increased the atrial flutter cycle length
immediately after administration. A representative example
of the effects of NAPA is shown in Figure 2; this atrial
flutter was induced after the control episode shown in Figure
1. NAPA increased the atrial flutter cycle length from 141
to 163 ms 30 seconds after administration, and also in-
creased the ventricular rate from 216 to 264 beats/min. Then
atrial flutter was interrupted 35 seconds after NAPA admin-
istration. The time course of changes in the atrial flutter
cycle length and ventricular rate during both the control
Figure 4. Representative example of the effects of quinidine (Q)
on atrial flutter induced in the same dog shown in Figures I and
2, but on a different day. Recordings are before and 30 seconds
and 2 and 6 minutes after quinidine administration. Quinidine
increased the atrial flutter cycle length (AFI-CL) but did not in-
terrupt the atrial flutter. After reaching its maximal prolongation,
the atrial fluttercycle lengthagain shortenedso that, at 15minutes,
it approached the baseline value. Abbreviations as in Figure I.
See text for discussion.
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episode of atrial flutter and the NAPA study is shown in
Figure 3 (left panel).
In the same dog, quinidine's effect on atrial flutter was
tested on a different day (Fig. 4). Although quinidine im-
mediately increased the atrial flutter cycle length from 139
to 174 ms and increased the ventricular rate from 216 to
270 beats/min as did NAPA, the atrial flutter was not in-
terrupted; rather, it was sustained. The time course of change
in the atrial flutter cycle length and the ventricular rate
during the control atrial flutter episode and the quinidine
study is shown in Figure 3 (right panel).
The results ofthe effects ofNAPA and quinidine on atrial
flutter are shown for all dogs in Figure 5. The maximal
changes in atrial flutter cycle length and ventricular rate
occurring after drug administration are indicated. Both NAPA
and quinidine increased atrial flutter cycle length signifi-
cantly. NAPA increased it from the mean baseline value of
118 ± 15 ms to the mean maximal value of 141 ± 18 ms
(p < 0.001) at a mean time of 88 seconds (range 0 to 360)
after administration. Quinidine increased it from a mean of
119 ± 17 ms to a mean maximum of 153 ± 21 ms (p <
0.001) at a mean time of 51 seconds (range 20 to 90). NAPA
increased the ventricular rate during atrial flutter in 6 of 12
dogs and decreased it in the remaining 6; thus the mean
value of the ventricular rate did not change (206 ± 49 and
208 ± 42 beats/min before and after NAPA, respectively).
On the other hand, quinidine increased the ventricular rate
in 9 of 10 dogs, and thus the mean ventricular rate increased
from 188 ± 54 to 236 ± 64 beats/min (p < 0.005).
Right after inducing the maximal increase of the atrial
flutter cycle length. NAPA interrupted atrial flutter in 11
(92%) of 12 dogs, whereas quinidine interrupted atrial flutter
in 6 (60%) of 10 dogs. Although NAPA interrupted atrial
flutter with a greater efficacy than did quinidine, this dif-
ference was not statistically significant. Quinidine inter-
rupted atrial flutter when the flutter cycle length was shorter
than 125 ms (six dogs, Fig. 5, closed circles). However, it
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150 bpm 300 bpm 150 bpm
Atriol Pacing Rate
Table 2. Influence of Atrial Flutter Induction on Atrial
Electrophysiologic Properties
26 ± 6
27 ± 4
28 ± 4
49 ± 6
50 ± 7
54 ± 9
2.2 ± 0.6
142 ± 16
After
Atrial Flutter
49 ± 6
50 ± 6
53 ± 9
26 ± 6
27 ± 5
28 ± 4
2.2 ± 0.6
142 ± 15
Before
Atrial Flutter
*Measured during atrial pacing at 150 beats/min .
Mean threshold of excitability (rnA)
Mean effective refractory period*
ST-PLA interval (ms)
150 beats/min
300 beats/min
400 beats/min
BB-PLA interval (ms)
150 beats/min
300 beats/min
400 beats/min
* p e 0.001
** p<O.OI
D Control~ NAPA ITill Quinidine
Effects of NAPA and Quinidine on Atrial
Electrophysiologic Properties
Threshold of excitability. Neither NAPA nor quinidine
changed the threshold of atrial excitability significantly. The
mean threshold of atrial excitability was 2.2 ± 0.6 rnA
both before and after NAPA administration and 2.3 ± 0.6
rnA both before and after quinidine administration.
Effective refractory period (Fig. 6). In all dogs, both
NAPA and quinidine prolonged the atrial effective refrac-
tory period measured at all three atrial sites. NAPA pro-
longed the mean atrial effective refractory period measured
during atrial pacing at 150 beats/min from 138 ± 17 to 168
± 21 ms (p < 0.001) and quinidine prolonged it from 136
± 14 to 148 ± 16 ms (p < 0.01). In five dogs in which
it could be determined, NAPA prolonged the mean atrial
effective refractory period measured during atrial pacing at
300 beats/min from 121 ± 9 to 142 ± 12 ms (p < 0.001).
When comparing the degree ofprolongation of the mean
effective refractory period caused by these two drugs. that
caused by NAPA was significantly greater than that caused
by quinidine (p < 0.001). Furthermore, in the six dogs in
which quinidine interrupted atrial flutter, the mean effective
200,---------------,
u
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w
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Figure 6. Effects of N-acetylprocainamide (NAPA) and quinidine
on the mean effective refractory period (ERP) of the atria measured
during atrial pacing at 150 and 300 beats/min. See text for dis-
cussion.
• AFI interrupted
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Figure 5. Effects of N-acetylprocainamide (NAPA) and quinidine
on the atrial flutter cycle length (AFl-CL) and ventricular rate (V-
Rate) during atrial flutter. The data shown are those before drug
administration and those at the time of maximal change (that is,
maximal prolongation of atrial flutter cycle length and maximal
increase or decrease of ventricular rate) occurring after drug admin-
istration. Horizontal bars indicate mean values. See text for dis-
cussion.
never interrupted atrial flutter with longer flutter cycle lengths
(four dogs, Fig. 5, open circles), although it increased the
atrial flutter cycle length in these four dogs to the same
degree as in the other six dogs. In contrast, the interruption
of atrial flutter by NAPA did not appear to be related to
atrial flutter cycle length.
Reinduction of atrial flutter was attempted after NAPA
and quinidine administration in nine and eight dogs, re-
spectively. Atrial flutter lasting more than 2 minutes was
reinduced in five (56%) of the nine and seven (88%) of the
eight dogs, respectively. The atrial flutter was then always
interrupted with rapid atrial pacing.
Influence of atrial flutter induction on atrial electro-
physiologic properties. The threshold of atrial excitability,
the atrial effective refractory period and markers of intra-
atrial conduction time during rapid rates (ST-PLA and BB-
PLA intervals) were measured in 12, 12 and 7 dogs, re-
spectively, both before and after a control episode of atrial
flutter (Table 2). None of these properties changed after the
control episode of atrial flutter. Thus, the prior induction
of atrial flutter and its subsequent termination by atrial pac-
ing did not affect these atrial electrophysiologic properties.
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N-acetylprocainamide (NAPA) (4-7) on atrial tissue, at least
at an atrial rate of 150 beats/min, Likewise, it confirms the
class IA antiarrhythmic drug effect of quinidine (15-17),
However, and more important, the fact that the effects of
NAPA and quinidine on the atrial electrophysiologic prop-
erties determined in this study were indistinguishable at
rapid pacing rates (that is, 300 and 400 beats/min) blurs the
distinction between these two categories of antiarrhythmic
agents, especially at rapid atrial rates in atrial tissue, It is
likely (though not established by this study) that in this
example, the prolongation of intraatrial conduction time at
atrial rates of 300 and 400 beats/min in the presence of
NAPA resulted from activation of atrial tissue before com-
plete repolarization of the atrial tissue at the point of the
advancing wave front from each paced beat.
Thus, we did not fully realize our hope that, by com-
paring the effects on atrial flutter of a drug that only prolongs
the atrial refractory period with those of a drug that not only
prolongs this period but also slows intraatrial conduction,
we would learn more about the nature of atrial flutter. What
did result was the clear demonstration that the action of
antiarrhythmic agents needs to be studied at different rates,
More specifically, it is clear from our study that to under-
stand the effects of a drug during a rapid rhythm, we cannot
simply extrapolate from data obtained from studies at rel-
atively slow rates but must study the agent's effects at rates
that approximate those of specific tachyarrhythmias for which
it might be used as therapy, In this regard, atrial flutter is
a most conspicuous example,
Effects of drugs on components of the reentrant loop.
More must be learned about the components of the reentrant
loop in this model of atrial flutter, and on what may be
differential effects of these drugs on different components
of this loop, Thus, what is the effect of these drugs on the
area of slow conduction in the reentrant loop? Is it different
from effects on other components of this loop? Although
we know that this model of atrial flutter has an excitable
gap because it can be transiently entrained and interrupted
by atrial pacing (11,12,18,19), we do not know if this gap
is fully or partially excitable, Thus, an understanding of the
effects of these agents on the excitable gap also is critical
for understanding the drug's effects and ability to interrupt
the arrhythmia when administered during an episode of the
tachycardia, Although the number of cases is small, the
greater degree of efficacy of NAPA (11 of 12 dogs) com-
pared with quinidine (6 of 10 dogs) in interrupting atrial
flutter in this experimental model may have several expla-
nations, These data not only seem intrinsically valid, but
also seem relevant to understanding treatment of atrial flutter
in humans, particularly because this experimental model has
a clinical counterpart (11),
An explanation for the interesting observation that quin-
idine interrupted six episodes of atrial flutter with very fast
rates but failed to interrupt (though it slowed) four episodes
400bpm300bpm
Atrial Pacing Rate
150 bpm
Figure7. Effects of N-acetylprocainamide (NAPA) and quinidine
on the conduction intervals stimulus to posteroinferior left atrium
(ST-PLA) and Bachmann's bundle to posteroinferior left atrium
(BB-PLA) measured during atrial pacing at 150, 300 and 400
beats/min. See text for discussion.
* p< 0.001
** p<O.Ol
o Control~ NAPA Iill1IQuinidine
(msec) ST-PlA interval
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NAPA versus quinidine in atrial flutter. The present
study confirms the class III antiarrhythmic drug effect of
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refractory period was prolonged from 131 ± 9 to 148 ±
16 ms (p < 0,025), whereas in the four dogs in which
quinidine did not interrupt atrial flutter, it was prolonged
only from 142 ± 18 to 148 ± 18 ms (p = NS), The former
group of dogs seemed to have a shorter atrial effective
refractory period before drug administration than did the
latter, but there was no statistical difference,
Intraatrial conduction time (Fig. 7). NAPA did not
change the ST-PLA or BB-PLA intervals during atrial pac-
ing at 150 beats/min, whereas it significantly increased these
intervals during atrial pacing at 300 and 400 beats/min, On
the other hand, quinidine significantly increased both of
these intervals during atrial pacing at all three rates (that is,
150, 300 and 400 beats/min), When comparing atrial con-
duction times in the dogs in which quinidine interrupted
atrial flutter with those in which it did not, there was no
statistical difference in quinidine's effect on these intervals,
Thus, NAPA affected atrial conduction time only during
high rate pacing, whereas quinidine affected it at all rates
studied (that is, the relatively slow rate of ISO beats/min,
and the fast rates of 300 and 400 beats/min),
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of atrial flutter with relatively slower rates is not readily
apparent. Analysis of the data, however, does suggest an
important role for the atrial effective refractory period. Thus,
quinidine interrupted atrial flutter in six dogs in which it
significantly prolonged this period and slowed intraatrial
conduction, whereas it did not interrupt atrial flutter in the
remaining four dogs in which it slowed intraatrial conduc-
tion significantly but did not significantly prolong this pe-
riod. This and the facts that NAPA I) did interrupt atrial
flutter in three of these four dogs (all four dogs appeared
to have the same atrial flutter during both the NAPA study
and the quinidine study because the cycle lengths of the
atrial flutter induced during each study were similar [Fig.
2 and 4]), and 2) also significantly prolonged the atrial
effective refractory period in these dogs strongly suggest
that the effect of NAPA on the refractory period played a
most important role in interrupting atrial flutter.
Conclusion. Although more detailed studies are nec-
essary to answer all the questions concerning the effects of
N-acetylprocainamide (NAPA) and quinidine on atrial flut-
ter in this canine model, our study provides several impor-
tant and interesting observations. First, the canine pericar-
ditis model, which does have a clinical counterpart, is a
suitable model for studying the effects of an antiarrhythmic
drug on atrial flutter. Second, the efficacy of NAPA in
interrupting atrial flutter when it is administered intrave-
nously seems importantly related to significant prolongation
of the effective refractory period. NAPA's efficacy also
suggests it may be a useful agent for short-term drug in-
terruption of atrial flutter in man. Third, our study clearly
indicates the need to assess the effects of a drug at very
rapid heart rates in addition to its effects at normal and
moderately rapid rates.
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